Syzygium polycephalum (Miq.) Merr. FRAP: 1338.37 ± 7.04; CUPRAC: 771.91 ± 8.78 mg AEAC/g) and alpha-glucosidase inhibitory activities (52,145.16 ± 801.54 mg AEAGIC/g). LC–HRMS/MS identified four compounds, including chrysin and formononetin. Integrated in silico analyses revealed that chrysin consistently outperformed other metabolites, exhibiting optimal docking scores, favorable absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties, and superior dynamic stability and binding affinity in molecular dynamics simulations. Collectively, these results position chrysin as the dominant bioactive driver and establish S. polycephalum leaf as a promising and sustainable source of dual-acting antioxidant and antidiabetic agents.
Rahmiyani et al. (Mon,) studied this question.